Peter Martin
Professor of Medicine, Chief of Lymphoma Program
Weill Cornell Medicine · New York, United States
Chief of the Lymphoma Program at Weill Cornell. Led the landmark SHINE trial demonstrating the benefit of adding ibrutinib to bendamustine-rituximab in older MCL patients.
MRD-driven initial therapy of acalabrutinib and lenalidomide plus rituximab or obinutuzumab for mantle cell lymphoma.
Blood advances · Feb 24, 2026
Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphoma.
Blood advances · Feb 24, 2026
Incidence of Occult Malignancy Diagnosed on Histopathology in Routine Adult Tonsillectomies.
The Laryngoscope · Feb 1, 2026
Pretargeted Anti-CD20 Radioimmunotherapy with scFv Fusion Protein Safely Combines with BEAM and ASCT in Patients with High-risk B-cell Lymphomas.
Molecular cancer therapeutics · Dec 2, 2025
Functional genomics and tumor microenvironment analysis reveal prognostic biological subtypes in Mantle cell lymphoma.
Nature communications · Nov 5, 2025
Leveraging BRG1 Driven Ferroptosis Resistance to Overcome Treatment Resistance.
bioRxiv : the preprint server for biology · Sep 5, 2025
Improvements in Outcomes in Older Patients With Mantle Cell Lymphoma Are Associated With Improvements Across Multiple Lines of Therapy.
Clinical lymphoma, myeloma & leukemia · Jun 1, 2025
TP53 Mutations Detected by NGS Are a Major Clinical Risk Factor for Stratifying Mantle Cell Lymphoma.
American journal of hematology · May 1, 2025
Randomized study of induction with bendamustine-rituximab ± bortezomib and maintenance with rituximab ± lenalidomide for MCL.
Blood · Sep 5, 2024
Does TRIANGLE take down transplantation in mantle cell lymphoma?
Lancet (London, England) · May 25, 2024
Novel treatment for mantle cell lymphoma - impact of BTK inhibitors and beyond.
Leukemia & lymphoma · Jan 1, 2024